Gabriel Alzial

Gabriel Alzial

Auto-generated profile, based on publicly available information

Gabriel Alzial

Université de Montréal 4 Montreal, Quebec

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2021 in Oncogene
Verified
Journal Article
Open access
PDF file
GAGabriel Alzial
Gabriel Alzial
OROphelie Renoult
Ophelie Renoult
FPFrançois Paris
François Paris
CGCatherine Gratas
Catherine Gratas
ACAnne Clavreul
Anne Clavreul
CPClaire Pecqueur
Claire Pecqueur
Brain tumors actively reprogram their cellular metabolism to survive and proliferate, thus offering potential therapeutic opportunities. Over the past decade, extensive research has been done on mutant IDH enzymes as markers of good prognosis in glioblastoma, a highly aggressive brain tumor in adults with dismal prognosis. Yet, 95% of glioblastoma are IDH wild-type. Here, we review current knowledge about IDH wild-type enzymes and their putative role in mechanisms driving tumor progression. After a brief overview on tumor metabolic adaptation, we present the diverse metabolic function of IDH enzymes and their roles in glioblastoma initiation, progression and response to treatments. Finally, we will discuss wild-type IDH targeting in primary glioblastoma.

1 January 2023
Verified
Book Chapter
Closed access
PDF file
MFMarina Fukano
Marina Fukano
GAGabriel Alzial
Gabriel Alzial
RLRaphaëlle Lambert
Raphaëlle Lambert
GDGeneviève Deblois
Geneviève Deblois

28 October 2026 in Cancer Research
Verified
Journal Article
Closed access
LPLucas Porras
Lucas Porras
MCMarina Carrière
Marina Carrière
AGAnn-Sophie Gironne
Ann-Sophie Gironne
HPHugo Philippeau
Hugo Philippeau
GAGabriel Alzial
Gabriel Alzial
GDGeneviève Deblois
Geneviève Deblois
Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the histone methyltransferase complex polycomb repressive complex 2, is overexpressed and associated with a poor prognosis in triple-negative breast cancer (TNBC). Although EZH2 inhibition significantly alters chromatin landscapes and gene expression, it has a limited impact on the growth of TNBC models, suggesting adaptive compensatory mechanisms. In this study, we demonstrated that EZH2 inhibition causes the accumulation of misfolded proteins and double-stranded RNA, triggering an essential integrated stress response (ISR) through protein kinase R and protein kinase RNA–like endoplasmic reticulum kinase activation. By inducing ISR-mediated activating transcription factor 4 (ATF4), EZH2 inhibition enhanced amino acid flux and promoted glutaminolysis to support TNBC cell survival. Pharmacologic targeting of this metabolic axis with a glutaminase inhibitor in combination with EZH2 inhibition significantly impaired TNBC cell proliferation and tumor growth. These findings reveal a stress-driven metabolic adaptation that sustains TNBC survival upon EZH2 blockade and highlight the inhibition of this pathway as a strategy to enhance the efficacy of EZH2 inhibitors in TNBC. Significance: By inducing integrated stress response–ATF4-mediated metabolic rewiring, EZH2 inhibition creates a critical glutamine dependency in triple-negative breast cancer, exposing an actionable vulnerability through co-inhibition of glutaminase.